Evidence map›Paper›PMID 41993393›Full record

ArticlebioRxiv : the preprint server for biology2026

Glucokinase activity suppresses hepatic cholesterol synthesis and triglyceride accumulation: A new model for the effects of the GKRP P466L common human variant.

Dominic Santoleri, Sarah Traynor, Ryan Calhoun, Matthew J Gavin, David Merrick, Patrick Seale, Paul M Titchenell

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Dominic SantoleriInstitute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania.ORCID 0000-0002-4468-6564
Sarah TraynorInstitute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania.ORCID 0000-0001-5484-2180
Ryan CalhounInstitute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania.
Matthew J GavinInstitute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania.
David MerrickInstitute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania.ORCID 0000-0001-6464-2705
Patrick SealeInstitute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania.ORCID 0000-0001-7119-1615
Paul M TitchenellInstitute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania.ORCID 0000-0002-9941-5649

Funding

VIRAL VECTOR COREP30DK019525 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI DOUGLAS J EPSTEIN · 1986 to 2026
$48.3M
Functional Interrogation of T2D-associated genes in human stem cell-derived models and miceUM1DK126194 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GRANT, STRUAN F A, KAESTNER, KLAUS H · 2020 to 2024
$8.8M
Hepatic mTORC1 Signaling and the Regulation of Lipid HomeostasisR01DK125497 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI TITCHENELL, PAUL MICHAEL · 2021 to 2024
$1.7M
Glucokinase Regulation of Hepatic MetabolismK01DK111715 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI TITCHENELL, PAUL MICHAEL · 2016 to 2019
$591k
NIDDK NIH HHS K01 DK111715NIDDK NIH HHS P30 DK019525NIDDK NIH HHS R01 DK125497NIDDK NIH HHS UM1 DK126194
6 · The paper itself

Abstract

Objective: Glucokinase Regulatory Protein (GKRP) controls the activity of Glucokinase (GCK) to regulate liver glucose uptake and storage. Coding variants in Methods: We developed mouse models to examine how the human GKRP P446L variant influences liver and systemic metabolism. Endogenous Gckr expression was ablated in adult mouse hepatocytes, together with re-expression of either human GKRP P446L or the reference GKRP protein. We assessed body weight, adiposity, systemic glucose homeostasis, and hepatic metabolites in mice expressing reference GKRP or GKRP P446L under multiple metabolic conditions. To determine whether the effects of GKRP P446L may result from reduced GCK activity, we analyzed mice with liver-specific deletion of Results: Hepatic expression of GKRP P446L resulted in reduced GKRP and GCK protein levels and elevated serum cholesterol. Hepatic deletion of Conclusions: The GKRP P446L variant reduced GKRP protein abundance, and diminished GCK activity while increasing cholesterol levels. Loss of GCK elevated cholesterol and hepatic triglyceride levels. Collectively, these findings demonstrate that GCK suppresses hepatic cholesterol synthesis and lipid accumulation, suggesting that reduced GCK activity underlies the metabolic abnormalities associated with the GKRP P446L variant.

Indexed as

cholesterol synthesisfatty liverGKRP P446LGlucokinase (GCK)Glucokinase Regulatory Protein (GKRP)

Identifiers

PMID41993393
PMCPMC13081813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.